Payment overview · 2025
General Payments
$35,589.35
93 reported records · 15 companies
Healthcare provider profile · identity verified
Evan D Schoenberg, MD
Allopathic & Osteopathic Physicians|Ophthalmology · ATLANTA, GA · NPI 1073747465
Verified facts
What the public records show
CMS Open Payments records show Evan D Schoenberg, MD received $35,589.35 in general payments during 2025 across 93 reported records.
Dompe US, Inc. accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cequa, Miebo, Oxervate, Xdemvy.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLENSA as an associated drug or biological on 18 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolensa by this doctor in 2024.
Dompe US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OXERVATE as an associated drug or biological on 19540 records involving 9712 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Oxervate by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FLAREX as an associated drug or biological on 39 records involving 37 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Flarex by this doctor in 2024.
SUN PHARMACEUTICAL INDUSTRIES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cequa as an associated drug or biological on 25765 records involving 9461 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Cequa by this doctor in 2024.
Tarsus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XDEMVY as an associated drug or biological on 46638 records involving 15254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xdemvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $14,029.06 | 39.4% | 21 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $12,720.80 | 35.7% | 18 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $7,399.80 | 20.8% | 17 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $353.05 | 1.0% | 15 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $177.08 | 0.5% | 4 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $154.53 | 0.4% | 2 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $145.87 | 0.4% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $144.71 | 0.4% | 3 | 2025 |
| Samsara Vision | Unresolved — no canonical attribution shown | $114.36 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.53 | 0.3% | 2 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.59 | 0.3% | 3 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $61.34 | 0.2% | 2 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $43.07 | 0.1% | 2 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $26.39 | 0.1% | 1 | 2025 |
| Rayner Intraocular Lenses Limited | Unresolved — no canonical attribution shown | $23.17 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $18,870.26 | 11 |
| Compensation for serving as faculty or as a speaker for a medical education program | $11,700.00 | 4 |
| Food and Beverage | $2,861.80 | 66 |
| Travel and Lodging | $2,068.29 | 11 |
| Education | $89.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $14,029.06 | 21 | 2025 |
Source payment records
|
|||||
| iStent inject Trabecular Micro-Bypass System Model G2-M-IS Normalized: istent inject trabecular micro bypass system model g2 m is |
Device | Glaukos Corporation | $11,125.00 | 6 | 2025 |
Source payment records
|
|||||
| Tecnis Simplicity Normalized: tecnis simplicity |
Device | Johnson & Johnson Surgical Vision, Inc. | $6,596.00 | 7 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $5,954.34 | 11 | 2025 |
Source payment records
|
|||||
| KXL System Normalized: kxl system |
Device | Glaukos Corporation | $1,200.00 | 1 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $242.84 | 9 | 2025 |
Source payment records
|
|||||
| KXL system (not refurbished) Normalized: kxl system not refurbished |
Device | Glaukos Corporation | $185.02 | 3 | 2025 |
Source payment records
|
|||||
| Clareon PanOptix Pro Normalized: clareon panoptix pro |
Device | Alcon Vision LLC | $184.72 | 7 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $177.08 | 4 | 2025 |
Source payment records
|
|||||
| VERITAS Vision System Normalized: veritas vision system |
Device | Johnson & Johnson Surgical Vision, Inc. | $165.00 | 1 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $154.53 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $154.53 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $154.53 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $154.53 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $154.53 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $144.71 | 3 | 2025 |
Source payment records
|
|||||
| CATALYS SYSTEM Normalized: catalys system |
Device | Johnson & Johnson Surgical Vision, Inc. | $144.40 | 2 | 2025 |
Source payment records
|
|||||
| Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz) Normalized: implantable miniature telescope imt by dr isaac lipshitz |
Device | Samsara Vision | $114.36 | 1 | 2025 |
Source payment records
|
|||||
| Clareon Normalized: clareon |
Device | Alcon Vision LLC | $105.85 | 6 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $101.53 | 2 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $94.59 | 3 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $61.34 | 2 | 2025 |
Source payment records
|
|||||
| Rhopressa Normalized: rhopressa |
Drug | Alcon Vision LLC | $31.31 | 1 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $31.17 | 1 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| RAYNER CATARACT SET 1 Normalized: rayner cataract set 1 |
Device | Rayner Intraocular Lenses Limited | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| RayOne Aspheric Normalized: rayone aspheric |
Device | Rayner Intraocular Lenses Limited | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| RayOne EMV Normalized: rayone emv |
Device | Rayner Intraocular Lenses Limited | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| RayOne Spheric Normalized: rayone spheric |
Device | Rayner Intraocular Lenses Limited | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| enVista Aspire IOL Normalized: envista aspire iol |
Device | Bausch & Lomb Americas Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cequa cequa |
2025 | Cequa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OXERVATE oxervate |
2025 | Oxervate | 2024 | 44 | exact normalized | Medicare Part D |
| XDEMVY xdemvy |
2025 | Xdemvy | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | PROLENSA open payments reported associated product |
CMS Open Payments — General Payments 18 supporting records · 13 recipient NPIs · example record 1254766966 |
Prolensa · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| Dompe US, Inc. Exact reporting entity; no affiliate inference |
2025 | OXERVATE open payments reported associated product |
CMS Open Payments — General Payments 19540 supporting records · 9712 recipient NPIs · example record 1248849978 |
Oxervate · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | FLAREX open payments reported associated product |
CMS Open Payments — General Payments 39 supporting records · 37 recipient NPIs · example record 1236210819 |
Flarex · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. Exact reporting entity; no affiliate inference |
2025 | Cequa open payments reported associated product |
CMS Open Payments — General Payments 25765 supporting records · 9461 recipient NPIs · example record 1250962431 |
Cequa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Tarsus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | XDEMVY open payments reported associated product |
CMS Open Payments — General Payments 46638 supporting records · 15254 recipient NPIs · example record 1233825434 |
Xdemvy · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 216 | 121 |
| Fluorometholone | Fluorometholone | 126 | 46 |
| Gatifloxacin | Gatifloxacin | 108 | 62 |
| Moxifloxacin | Moxifloxacin Hcl | 79 | 39 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 71 | 58 |
| Oxervate | Cenegermin-Bkbj | 44 | 11 |
| Valacyclovir | Valacyclovir Hcl | 33 | 16 |
| Timolol Maleate | Timolol Maleate | 32 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | suppressed |
| Flarex | Fluorometholone Acetate | 31 | suppressed |
| Latanoprost | Latanoprost | 25 | 11 |
| Xdemvy | Lotilaner | 22 | 21 |
| Prolensa | Bromfenac Sodium | 21 | 13 |
| Cequa | Cyclosporine | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Restasis | Cyclosporine | 14 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Miebo | Perfluorohexyloctane/Pf | 13 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 13 | 12 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Lotemax Sm | Loteprednol Etabonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35,589.35 · 93 records | Dompe US, Inc. | ACTHAR, CATALYS SYSTEM, Cequa, Clareon, Clareon PanOptix Pro, Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz), KXL System, KXL system (not refurbished), LIGHT ADJUSTABLE LENS (LAL), MIEBO, OXERVATE, Photrexa Viscous and Photrexa, RAYNER CATARACT SET 1, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), RayOne Aspheric, RayOne EMV, RayOne Spheric, Rhopressa, TECNIS IOL, TEPEZZA, TRYPTYR, TYRVAYA, Tecnis Simplicity, VERITAS Vision System, VEVYE, XDEMVY, XIIDRA, enVista Aspire IOL, iStent inject Trabecular Micro-Bypass System Model G2-M-IS | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cequa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bausch & Lomb Americas Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error